18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Improvement in Pulmonary Status by Two Categories on an 8 Point Ordinal Scale of Respiratory FunctionPrimary· baseline, through hospital discharge or death
8-Point Ordinal Scale of Respiratory Function: 8 -Death; 7 -Ventilation in addition to extracorporeal membrane oxygen (ECMO), continuous renal replacement therapy (CRRT), or need for vasopressors (dopamine ≥5 μg/kg/min OR epinephrine ≥0.1 μg/kg/min OR norepinephrine ≥0.1 μg/kg/min) 6 -Intubation and mechanical ventilation 5 -Non-invasive mechanical ventilation (NIV) or high-flow oxygen 4 -Hospitalized, requiring oxygen by mask or nasal prongs 3 -Hospitalization without oxygen supplementation 2-Discharged from hospital either to home with supplemental oxygen OR to inpatient rehabilitation/skill
Group
Value
95% CI
Cohort 1 - Etoposide
2
Cohort 1 - Control
1
Overall SurvivalSecondary· 30 Days
Number of participants that lived to day 30 or hospital discharge
Group
Value
95% CI
Cohort 1 - Etoposide
3
Cohort 1 - Control
1
Length of HospitalizationSecondary· From date of enrollment until date of discharge
Number of days participants were hospitalized after treatment
Group
Value
95% CI
Cohort 1 - Etoposide
17
± 11.35
Cohort 1 - Control
24
± 5.66
Duration of Ventilation After TreatmentSecondary· From date of enrollment until the date of extubation
Number of days participants were ventilated after treatment
Group
Value
95% CI
Cohort 1 - Etoposide
15.67
± 12.9
Cohort 1 - Control
15.0
± 0
Change in Blood Ferritin LevelsSecondary· baseline, to day 30 (or discharge or death)
Change in ferritin from treatment to day 30
Group
Value
95% CI
Cohort 1 - Etoposide
1235.67
± 1180.59
Cohort 1 - Control
-1771.50
± 2320.02
Change in C-reactive Protein (CRP) LevelsSecondary· baseline, to day 30 (or discharge or death)
Change in CRP levels from treatment to day 30
Group
Value
95% CI
Cohort 1 - Etoposide
-49.00
± 64.38
Cohort 1 - Control
-74.00
± 63.64
Change in D-dimer Blood LevelsSecondary· baseline, to day 30 (or discharge or death)
Change in d-dimer from treatment to day 30
Group
Value
95% CI
Cohort 1 - Etoposide
480.67
± 2427.12
Cohort 1 - Control
-2243.00
± 3618.97
Change in White Blood Cell CountSecondary· baseline, to day 30 (or discharge or death)
Change in white blood cell count from treatment to day 30
Group
Value
95% CI
Cohort 1 - Etoposide
5.18
± 6.35
Cohort 1 - Control
13.40
± 10.04
Change in Platelet CountSecondary· baseline, to day 30 (or discharge or death)
Change in platelet count from treatment to day 30
Group
Value
95% CI
Cohort 1 - Etoposide
-70.00
± 100.84
Cohort 1 - Control
102.00
± 72.12
Adverse events — posted to ClinicalTrials.gov
Time frame: Treatment/enrollment until discharge or death.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is a randomized, open-label phase II study designed to evaluate the safety and efficacy of etoposide in patients with the 2019 novel coronavirus (COVID-19) infection. Randomization will be performed with a 3:1 allocation ratio. Treatment will be comprised of etoposide administered intravenously at a dose of 150 mg/m2 on Days 1 and 4 in patients with COVID-19 infection meeting eligibility criteria. Subsequent doses of etoposide will be allowed if the investigator and treating physician believe the patient had clinical benefit from etoposide therapy but subsequently has evidence of recurrent clinical deterioration. Subjects randomized to control will receive standard of care treatment. No placebo will be used.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06738368 — Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin
· Phase 2
· recruiting
NCT06406465 — A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
· Phase 2
· recruiting
NCT07525466 — Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm
· Phase 1, PHASE2
· recruiting
NCT07321912 — Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
· Phase 2
· not yet recruiting
NCT07224100 — Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosom
· Phase 2
· recruiting
Other recruiting trials for COVID-19
Currently open trials in the same condition.
NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults
· Phase 1
· active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
· Phase 3
· active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
· Phase 1
· recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
· Phase 2
· recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A
· Phase 3
· active not recruiting
Other Boston Medical Center trials
Trials by the same sponsor.
NCT06679114 — Preventing Mental Disorders Among Women Internally Displaced by War in Ukraine: The SHAWL Trial
· NA
· completed
NCT06093893 — Hypotensive Anesthesia for Orthognathic Surgery
· Phase 4
· completed
NCT06489522 — Parenting Intervention for Mothers With Substance Use Disorder
· NA
· completed
NCT05769218 — PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study
· NA
· recruiting
NCT06427967 — A Novel Social Emotional Learning Curriculum for Youth With Epilepsy
· NA
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boston Medical Center
Last refreshed: 15 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04356690.